JNJ-40411813

DRUG7 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

ConfusionFocal Onset SeizuresHealthyMajor Depressive DisorderPerceptual DisordersSchizophrenia

Phase 1

Ketamine Challenge Study With JNJ-40411813

CompletedNCT01101659

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Confusion, Perceptual Disorders, Schizophrenia

Start: 2010-02-28End: 2010-07-31Updated: 2014-04-08

A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers

CompletedNCT01358006

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy

Start: 2010-11-30End: 2011-03-31Updated: 2013-07-09

A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients

CompletedNCT01951053

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy

Start: 2010-01-31End: 2010-05-31Updated: 2013-09-26

A Study of JNJ-40411813 in Healthy Japanese Male Participants

CompletedNCT04677530

Janssen Pharmaceutical K.K.Healthy

Start: 2021-01-29End: 2021-05-21Updated: 2025-04-28

Phase 2

Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

CompletedNCT01323205

Janssen Research & Development, LLCSchizophrenia

Start: 2011-05-31End: 2012-12-31Updated: 2014-05-30

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

CompletedNCT01582815

Janssen Research & Development, LLCMajor Depressive Disorder

Start: 2012-09-30End: 2013-11-30Updated: 2015-06-16

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

CompletedNCT04836559

Janssen Research & Development, LLCFocal Onset Seizures

Start: 2021-05-18End: 2024-02-08Updated: 2025-07-03